Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextbiomedical CoXKRX:389650 +1.82%38 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates XKRX:389650 with a GF Score™ of 38/100. The stock has 1 warning sign investors should review. Among 378 Biotechnology companies, Nextbiomedical Co ranks worse than 264550% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Nextbiomedical Co's
Operating Income
for the
three
months ended in Jun. 2026 was ₩-1,034 Mil. Nextbiomedical Co's Interest Expense for the
three
months ended in Jun. 2026 was ₩-68 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Nextbiomedical Co's Interest Coverage or its related term are showing as below:
XKRX:389650's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 105.09 * Ranked among companies with meaningful Interest Coverage only.
Nextbiomedical Co (XKRX:389650) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Nextbiomedical Co Interest Coverage Related Terms
Nextbiomedical Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Nextbiomedical Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XKRX:389650 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Nextbiomedical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextbiomedical Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nextbiomedical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Nextbiomedical Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Nextbiomedical Co did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Nextbiomedical Co (XKRX:389650) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nextbiomedical Co and its competitors. According to the industry distribution chart, Nextbiomedical Co ranks #999999 out of 378 companies in the Biotechnology industry.
Is Nextbiomedical Co's Interest Coverage too high?
Nextbiomedical Co's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Nextbiomedical Co ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nextbiomedical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nextbiomedical Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nextbiomedical Co ranks #999999 out of 378 companies for Interest Coverage. This places Nextbiomedical Co in the lower half of its industry. The industry median Interest Coverage is 105.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 105.09, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nextbiomedical Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 105.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nextbiomedical Co's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextbiomedical Co stock overvalued right now?
Nextbiomedical Co (XKRX:389650) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Nextbiomedical Co's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Nextbiomedical Co (XKRX:389650), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
38GF Score
Get the complete analysis for XKRX:389650
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:389650 has been successfully added to your 
